These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1073 related articles for article (PubMed ID: 10469288)

  • 1. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial.
    Marcus R; Holloway L; Wells B; Greendale G; James MK; Wasilauskas C; Kelaghan J
    J Bone Miner Res; 1999 Sep; 14(9):1583-95. PubMed ID: 10469288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
    J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.
    Ensrud KE; Barrett-Connor EL; Schwartz A; Santora AC; Bauer DC; Suryawanshi S; Feldstein A; Haskell WL; Hochberg MC; Torner JC; Lombardi A; Black DM;
    J Bone Miner Res; 2004 Aug; 19(8):1259-69. PubMed ID: 15231012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy.
    Rogers A; Glover SJ; Eastell R
    Bone; 2009 Dec; 45(6):1044-52. PubMed ID: 19665601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of continuous oestradiol with intermittent norgestimate on bone mineral density and bone turnover in post-menopausal women.
    Arrenbrecht S; Caubel P; Garnero P; Felsenberg D
    Maturitas; 2004 Jul; 48(3):197-207. PubMed ID: 15207885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation.
    Rosen CJ; Chesnut CH; Mallinak NJ
    J Clin Endocrinol Metab; 1997 Jun; 82(6):1904-10. PubMed ID: 9177404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis.
    Garnero P; Sornay-Rendu E; Chapuy MC; Delmas PD
    J Bone Miner Res; 1996 Mar; 11(3):337-49. PubMed ID: 8852944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial.
    Bauer DC; Black DM; Garnero P; Hochberg M; Ott S; Orloff J; Thompson DE; Ewing SK; Delmas PD;
    J Bone Miner Res; 2004 Aug; 19(8):1250-8. PubMed ID: 15231011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Body mass index (BMI) and parameters of bone formation and resorption in postmenopausal women.
    Papakitsou EF; Margioris AN; Dretakis KE; Trovas G; Zoras U; Lyritis G; Dretakis EK; Stergiopoulos K
    Maturitas; 2004 Mar; 47(3):185-93. PubMed ID: 15036488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Marked increases in bone mineral density and biochemical markers of bone turnover in patients with anorexia nervosa gaining weight.
    Viapiana O; Gatti D; Dalle Grave R; Todesco T; Rossini M; Braga V; Idolazzi L; Fracassi E; Adami S
    Bone; 2007 Apr; 40(4):1073-7. PubMed ID: 17240212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect.
    Eisman JA; Bone HG; Hosking DJ; McClung MR; Reid IR; Rizzoli R; Resch H; Verbruggen N; Hustad CM; DaSilva C; Petrovic R; Santora AC; Ince BA; Lombardi A
    J Bone Miner Res; 2011 Feb; 26(2):242-51. PubMed ID: 20740685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
    Deal C; Omizo M; Schwartz EN; Eriksen EF; Cantor P; Wang J; Glass EV; Myers SL; Krege JH
    J Bone Miner Res; 2005 Nov; 20(11):1905-11. PubMed ID: 16234962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
    Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
    Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
    Perez EA; Josse RG; Pritchard KI; Ingle JN; Martino S; Findlay BP; Shenkier TN; Tozer RG; Palmer MJ; Shepherd LE; Liu S; Tu D; Goss PE
    J Clin Oncol; 2006 Aug; 24(22):3629-35. PubMed ID: 16822845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of simvastatin on bone turnover and BMD: a 1-year randomized controlled trial in postmenopausal osteopenic women.
    Rejnmark L; Buus NH; Vestergaard P; Heickendorff L; Andreasen F; Larsen ML; Mosekilde L
    J Bone Miner Res; 2004 May; 19(5):737-44. PubMed ID: 15068496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism.
    Guo CY; Thomas WE; al-Dehaimi AW; Assiri AM; Eastell R
    J Clin Endocrinol Metab; 1996 Oct; 81(10):3487-91. PubMed ID: 8855790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis.
    Dane C; Dane B; Cetin A; Erginbas M
    Gynecol Endocrinol; 2007 Jul; 23(7):398-403. PubMed ID: 17701771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical markers as predictors of rates of bone loss after menopause.
    Rogers A; Hannon RA; Eastell R
    J Bone Miner Res; 2000 Jul; 15(7):1398-404. PubMed ID: 10893690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
    Chen P; Satterwhite JH; Licata AA; Lewiecki EM; Sipos AA; Misurski DM; Wagman RB
    J Bone Miner Res; 2005 Jun; 20(6):962-70. PubMed ID: 15883636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis.
    Zhang ZL; He JW; Qin YJ; Huang QR; Liu YJ; Hu YQ; Li M
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr; 23(2):129-33. PubMed ID: 16604479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.